<DOC>
	<DOCNO>NCT01002560</DOCNO>
	<brief_summary>The purpose project analyze tumour tissue group subject malignant melanoma , treat Royal Marsden Hospital .</brief_summary>
	<brief_title>The Identification Novel Prognostic Markers Melanoma</brief_title>
	<detailed_description>Background - The Royal Marsden Hospital Institute Cancer Research constitute large comprehensive cancer centre Europe . In addition in-house drug development program , phase I - phase III clinical trial novel anti-cancer agent host . In order investigate optimal use novel molecularly target agent , access clinical tumour sample need order determine particular cancer type express molecular `` signature '' may indicate potential therapeutic utility . Understanding signature accelerate registration new drug routine cancer therapy ; offer potential selecting patient tumour type likely benefit therapy . Furthermore , new insight disease biology may gain . Main research question/ objective - Are feature primary melanoma lymph node metastasis predict subsequent clinical outcome well exist marker ?</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Diagnosis melanoma Adequate paraffinembedded material available analysis . Adequate clinical followup information Written inform consent applicable Inadequate paraffinembedded material available Inadequate clinical followup information .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Novel Prognostic Markers</keyword>
</DOC>